| scholarly article | Q13442814 |
| P50 | author | Frederick M. Ausubel | Q15989696 |
| Anne E Carpenter | Q50597627 | ||
| Ralph Mazitschek | Q56209230 | ||
| P2093 | author name string | Gang Wu | |
| Annie L Conery | |||
| Jonah Larkins-Ford | |||
| Ralph Mazitschek | |||
| Kim Lewis | |||
| Gabriele Casadei | |||
| Terence I Moy | |||
| P2860 | cites work | A small-molecule screen in C. elegans yields a new calcium channel antagonist | Q59065594 |
| Characterization of a germ-line proliferation mutation in C. elegans | Q67817522 | ||
| Where will new antibiotics come from? | Q79817299 | ||
| CellProfiler: image analysis software for identifying and quantifying cell phenotypes | Q24676898 | ||
| A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays | Q28145712 | ||
| Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis | Q28776658 | ||
| Maintenance of C. elegans | Q29617844 | ||
| Identification of novel antimicrobials using a live-animal infection model | Q33248011 | ||
| Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish | Q33308472 | ||
| An antidepressant that extends lifespan in adult Caenorhabditis elegans | Q34585284 | ||
| Seeing is believing: the impact of structural genomics on antimicrobial drug discovery | Q35889596 | ||
| Antibacterial drug discovery: is it all downhill from here? | Q35937148 | ||
| High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development | Q36094993 | ||
| A retrospective on the failures and successes of antibacterial drug discovery. | Q36207346 | ||
| The biology and future prospects of antivirulence therapies | Q36397902 | ||
| Targeting virulence for antibacterial chemotherapy: identifying and characterising virulence factors for lead discovery | Q36451405 | ||
| ChemBank: a small-molecule screening and cheminformatics resource database | Q36454111 | ||
| Has nature already identified all useful antibacterial targets? | Q37274160 | ||
| Antibacterial drug discovery: is small pharma the solution? | Q39217949 | ||
| SEK-1 MAPKK mediates Ca2+ signaling to determine neuronal asymmetric development in Caenorhabditis elegans | Q39750244 | ||
| Discovery of O-GlcNAc transferase inhibitors | Q46758608 | ||
| Models of Caenorhabditis elegans infection by bacterial and fungal pathogens. | Q52689855 | ||
| An automated high-throughput assay for survival of the nematode Caenorhabditis elegans. | Q53918669 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 527-533 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | ACS Chemical Biology | Q165583 |
| P1476 | title | High-throughput screen for novel antimicrobials using a whole animal infection model | |
| P478 | volume | 4 |
| Q37736587 | 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Caenorhabditis elegans as a model to study tissues involved in host immunity and microbial pathogenesis |
| Q34539031 | A High-Content, Phenotypic Screen Identifies Fluorouridine as an Inhibitor of Pyoverdine Biosynthesis and Pseudomonas aeruginosa Virulence |
| Q27320254 | A High-Throughput Small Molecule Screen for C. elegans Linker Cell Death Inhibitors |
| Q90236980 | A High-throughput, High-content, Liquid-based C. elegans Pathosystem |
| Q34793631 | A whole-organism screen identifies new regulators of fat storage |
| Q38647694 | Activity of a novel protonophore against methicillin-resistant Staphylococcus aureus |
| Q92932986 | Aminobenzylated 4-Nitrophenols as Antibacterial Agents Obtained from 5-Nitrosalicylaldehyde through a Petasis Borono-Mannich Reaction |
| Q36208358 | An image analysis toolbox for high-throughput C. elegans assays |
| Q51530334 | An integrated microfluidic platform for evaluating in vivo antimicrobial activity of natural compounds using a whole-animal infection model. |
| Q38840796 | An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs |
| Q36479306 | Antibacterial properties of 3-(phenylsulfonyl)-2-pyrazinecarbonitrile |
| Q93067924 | Application of Synthetic Molecular Evolution to the Discovery of Antimicrobial Peptides |
| Q21562132 | Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin Z |
| Q38098597 | Automated imaging and other developments in whole-organism anthelmintic screening |
| Q64093701 | Automated morphometry toolbox for analysis of microscopic model organisms using simple bright-field imaging |
| Q28071846 | Beyond Traditional Antimicrobials: A Caenorhabditis elegans Model for Discovery of Novel Anti-infectives |
| Q37866903 | C. elegans: model host and tool for antimicrobial drug discovery |
| Q89211305 | Caenorhabditis elegans in high-throughput screens for anti-infective compounds |
| Q34986826 | Caenorhabditis elegans-based in vivo screening of bioactives from marine sponge-associated bacteria against Vibrio alginolyticus |
| Q33864072 | Caenorhabditis elegans-based model systems for antifungal drug discovery |
| Q90477581 | Caenorhabditis elegans: a model to understand host-microbe interactions |
| Q82876835 | Cell-based assays for high-throughput screening |
| Q40157296 | Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds |
| Q52621271 | Combined flow cytometry and high-throughput image analysis for the study of essential genes in Caenorhabditis elegans. |
| Q36625852 | Curcumin and neurodegenerative diseases |
| Q39946056 | Cyclic dipeptide cyclo(l-leucyl-l-prolyl) from marine Bacillus amyloliquefaciens mitigates biofilm formation and virulence in Listeria monocytogenes |
| Q33553477 | Development of gold nanoparticles coated with silica containing the antibiofilm drug cinnamaldehyde and their effects on pathogenic bacteria |
| Q37691418 | Developmental biomarkers of aging in Caenorhabditis elegans |
| Q38028520 | Discovery of novel antibacterials |
| Q35083772 | Discovery of potential anti-infectives against Staphylococcus aureus using a Caenorhabditis elegans infection model |
| Q26751067 | Diversity, evolution and medical applications of insect antimicrobial peptides |
| Q39039978 | Drug Discovery in Fish, Flies, and Worms |
| Q41944682 | EXTRACTING BIOMEDICALLY IMPORTANT INFORMATION FROM LARGE, AUTOMATED IMAGING EXPERIMENTS. |
| Q41815282 | Effective drug combination for Caenorhabditis elegans nematodes discovered by output-driven feedback system control technique. |
| Q38192499 | Enterococcus infection biology: lessons from invertebrate host models |
| Q24623064 | Evolution of host innate defence: insights from Caenorhabditis elegans and primitive invertebrates |
| Q28834438 | High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models |
| Q39629047 | High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model |
| Q36041627 | High-throughput screening in the C. elegans nervous system |
| Q28476138 | Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay |
| Q36864793 | Immune defense mechanisms in the Caenorhabditis elegans intestinal epithelium |
| Q36565579 | Impact of different cell penetrating peptides on the efficacy of antisense therapeutics for targeting intracellular pathogens. |
| Q37907310 | Implications of interspecies signaling for virulence of bacterial and fungal pathogens. |
| Q27316596 | In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feeding |
| Q35836858 | In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA. |
| Q37120398 | In vitro and in vivo characterization of a tunable dual-reactivity probe of the Nrf2-ARE pathway |
| Q35076900 | Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model |
| Q37776356 | Interkingdom signaling between pathogenic bacteria and Caenorhabditis elegans |
| Q47964862 | Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model. |
| Q28749568 | Introduction to the quantitative analysis of two-dimensional fluorescence microscopy images for cell-based screening |
| Q28292832 | It takes nerves to fight infections: insights on neuro-immune interactions from C. elegans |
| Q35099764 | Lactobacillus zeae protects Caenorhabditis elegans from enterotoxigenic Escherichia coli-caused death by inhibiting enterotoxin gene expression of the pathogen |
| Q38762268 | Measuring Caenorhabditis elegans life span in 96 well microtiter plates |
| Q42576216 | Models to study ancient host-pathogen interactions: lessons from Crete |
| Q62498988 | Morphology-guided graph search for untangling objects: C. elegans analysis |
| Q36485393 | On the Mechanism of Berberine-INF55 (5-Nitro-2-phenylindole) Hybrid Antibacterials |
| Q35836401 | Pharmacological maintenance of protein homeostasis could postpone age-related disease |
| Q27347875 | Phosphorylation of the conserved transcription factor ATF-7 by PMK-1 p38 MAPK regulates innate immunity in Caenorhabditis elegans |
| Q53687606 | Propyl-5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC): a new bacteriostatic agent against methicillin-resistant Staphylococcus aureus. |
| Q28289283 | Pseudomonas aeruginosa disrupts Caenorhabditis elegans iron homeostasis, causing a hypoxic response and death |
| Q35004955 | Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. |
| Q42220000 | RESOLVING CLUSTERED WORMS VIA PROBABILISTIC SHAPE MODELS |
| Q91382297 | RNAi Screening: Automated High-Throughput Liquid RNAi Screening in Caenorhabditis elegans |
| Q38819114 | Raf-kinase inhibitor GW5074 shows antibacterial activity against methicillin-resistant Staphylococcus aureus and potentiates the activity of gentamicin |
| Q28271536 | Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence |
| Q36747017 | Red Seaweeds Sarcodiotheca gaudichaudii and Chondrus crispus down Regulate Virulence Factors of Salmonella Enteritidis and Induce Immune Responses in Caenorhabditis elegans |
| Q90261920 | Repurposing bioactive compounds for treating multidrug-resistant pathogens |
| Q28546591 | Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus |
| Q39697699 | Screening cellular feature measurements for image-based assay development |
| Q41974659 | Small molecules aimed at type III secretion systems to inhibit bacterial virulence |
| Q27333654 | Stimulation of host immune defenses by a small molecule protects C. elegans from bacterial infection |
| Q36296637 | Stochastic assembly produces heterogeneous communities in the Caenorhabditis elegans intestine |
| Q52640792 | Strategies against methicillin-resistant Staphylococcus aureus persisters. |
| Q60311033 | Stress-responsive and metabolic gene regulation are altered in low S-adenosylmethionine |
| Q33825490 | Synthesis and antibacterial evaluation of a novel series of 2-(1,2-dihydro-3-oxo-3H-pyrazol-2-yl)benzothiazoles |
| Q35864807 | Systems biology of fungal infection. |
| Q26752975 | Targeting Staphylococcus aureus Toxins: A Potential form of Anti-Virulence Therapy |
| Q37139639 | Targeting listeria monocytogenes rpoA and rpoD genes using peptide nucleic acids. |
| Q92518188 | The C. elegans CHP1 homolog, pbo-1, functions in innate immunity by regulating the pH of the intestinal lumen |
| Q38204148 | The C. elegans lifespan assay toolkit. |
| Q28071970 | The C. elegans model in toxicity testing |
| Q27004910 | The early bird catches the worm: new technologies for the Caenorhabditis elegans toolkit |
| Q27325648 | The evolutionarily conserved mediator subunit MDT-15/MED15 links protective innate immune responses and xenobiotic detoxification |
| Q34167532 | The garden of antimicrobial delights |
| Q61812007 | The nuclear hormone receptor NHR-86 controls anti-pathogen responses in C. elegans |
| Q34459318 | The re-emergence of natural products for drug discovery in the genomics era. |
| Q37139366 | The role of mycelium production and a MAPK-mediated immune response in the C. elegans-Fusarium model system |
| Q38534653 | Unconventional screening approaches for antibiotic discovery |
| Q28552737 | Using C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic Activity |
| Q33936475 | Using C. elegans for antimicrobial drug discovery |
| Q58851744 | What role can metabolomics play in the discovery and development of new medicines for infectious diseases? |
| Q38642986 | Whole animal HTS of small molecules for antifungal compounds |
| Q28539903 | Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus |
| Q21144493 | Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases |
| Q52349670 | Whole-organism phenotypic screening for anti-infectives promoting host health. |
Search more.